FACT SHEET
Since 2006, Adamis Pharmaceuticals Corp. (OTCBB: ADMP) has quickly established
OTCBB: ADMP
Share Information
OTCQB: ADMP
(a fully-reporting company)
Recent price………………. $0.23
Outstanding shrs……. 81.6 million
Public float………… 47.2 million
52-week range……. $0.36 - $0.15
Avg. vol (90-days)……... 107,900
Market cap………… $18.8 million
Fiscal year end……... March 31st
Executive Mgmt.
Dennis J. Carlo, Ph.D.
President and CEO
Robert O. Hopkins, CFO
David J. Marguglio, Senior VP
Thomas Moll, Ph.D.
Vice President /Research
Karen K. Daniels
Vice President /Operations
Richard L. Aloi
Adamis Laboratories, President
Corporate Offices
Adamis Pharmaceuticals Corp.
11455 El Camino Real, Suite 310
San Diego, California 92130
Tel. # 858.997.2400
info@adamispharma.com
www.AdamisPharma.com
Company Fact Sheet...
produced by Heritage First Capital
& Equity Research Group
May 2011
their firm with an enviable product pipeline for making biopharmaceutical history.
By combining specialty pharmaceuticals and biotechnology, Adamis is creating powerful
medicines right now. They are unique and have more than one potential blockbuster
product in 3 major therapeutic areas, including: Allergy/Respiratory (Asthma/COPD),
Oncology (Cancer) and Immunology and Infectious Diseases (Viruses).
Recent Results Headline News
• Adamis Acquires Potential Universal Cancer Vaccine Technology 04/19/11
• Adamis Reports APC-300 Kills Human Pancreatic Cancer Cells 03/24/11
• Adamis Files IND for Product Candidate to Treat Prostate Cancer 03/09/11
• Adamis Announces Phase 3 Meets Primary Endpoint 12/07/10
• Adamis & Beximco Pharma Announce Manufacturing Agreement 12/01/10
• Adamis Completes $10 million Stock Purchase [Funding] Agreement 11/11/10
Adamis has two (2) wholly-owned subsidiaries:
Adamis Laboratories (specialty pharmaceuticals) is focused on
the allergy, respiratory and pediatric medicine markets. Along with
the epinephrine single dose syringe, they have 3 respiratory products in late stage develop.
Adamis Therapeutics, Inc. (biotechnology), is initially focusing on the development of
patented, proprietary technologies for the potential treatment of human prostate cancer.
♦ ♦ BLOCKBUSTER POTENTIAL ♦ ♦
Adamis Therapeutics is developing first-in-class products with “blockbuster” potential.
During the 4th quarter of 2010, the Company obtained exclusive worldwide rights to
three new compounds for the treatment of prostate cancer (see 10/19/10 news below).
SAN DIEGO -- Oct. 19, 2010 -- Adamis Pharmaceuticals Corporation (OTCBB: ADMP),
announced the acquisition from Colby Pharmaceuticals of the remaining exclusive license
agreements relating to the remaining 2 of 3 drug product candidates for the treatment of
prostate cancer (PCa). Adamis has now acquired the exclusive licenses covering
three (3) molecule compounds, named APC-100, APC-200 and APC 300.
Over $18 million in U.S. Govt. funds have been awarded for the development of APC-100,
APC-200 and APC-300, including: the Congressionally Directed Medical Research Program,
the Prostate Cancer Research Program, and the National Cancer Institute (NCI).
APC-100 has also been privately funded by Michael Milken's Prostate Cancer Foundation.
In 2006 and 2007, both the APC-100 and APC-200 compounds won the prestigious
National Cancer Institute Rapid Award, which is given to drugs the NCI considers to be
the most promising new drugs for the treatment or prevention of cancer.
Adamis Pharmaceuticals Corporation has strong patent claims in the United States
and in certain foreign markets with other foreign applications in progress.
DISCOVER WHY ADAMIS IS DEVELOPING A CANCER VACCINE
THEY BELIEVE IS SUPERIOR TO DENDEON CORP.’s PROVENGE ®
Page 2 ▼
Copyright © 2011 Heritage First Capital / www.heritagefirst.com / Tel. 407.444.5959 / Greater Orlando
 Potential Cancer Vaccine Blockbuster
Adamis Pharmaceuticals Corp.’s Prostate Cancer Vaccine:
TeloB-VAX
Adamis Therapeutics is developing a novel cell-based cancer vaccine, TeloB-VAX. OTCQB: ADMP
Adamis’ therapeutic cancer vaccine is conceptually distinct from the only FDA approved cell-based cancer vaccine, Provenge®
(Dendeon Corp./Nasdaq: DNDN), which is said to use the patient’s own dendritic cells (though it’s not definitively proven).

TeloB-VAX utilizes the patient’s own B cells as antigen producing and antigen presenting cells. (B cells represent approx. 12% of
circulating blood cells).

Adamis believes its technology offers major advantages over the FDA approved Provenge® vaccine. These advantages, include:

1) prolonged antigen presentation by B cells (5 days) as compared to the short presentation time by dendritic cells (12 hours),

2) a unique patented platform technology using a universal cancer antigen that is increased in approximately 85% of all tumors,

3) immunity after a single injection, 4) no need for complicated culture procedures, 5) significantly fewer steps and 6) lower cost

NOTE: TeloB-VAX may very well be called a “universal cancer vaccine” that could induce immunity against multiple cancer types
as well as targeting the specific cancer stem cell. Currently Adamis is planning a Phase 2 study in castrate resistant prostate cancer
(CRPC) patients. The study will be conducted at the University of Wisconsin Carbone Cancer Center and at UCSD.

Adamis expects to submit an IND application to the FDA during the second half of 2011.

Adamis Laboratories and their specialty pharmaceuticals are expected to generate significant revenues first. With several
new product candidates in the Allergy and Respiratory categories in the advanced stages of Adamis Labs’ development pipeline, the
Company is projecting profitability as early as 2012. These near market ready products include the Epinephrine Pre-Filled Syringe,
and HFA aerosolized Inhaled Nasal Steroid, and two respiratory pMDI product candidates for asthma and COPD.

Please see www.AdamisPharma.com for in-depth medical product descriptions, key attributes and market potential data.
The natural brevity of this fact sheet has excluded other significant corporate assets, including wholly-owned subsidiary, Adamis
Laboratories’ intellectual property rights for a microbicide contraception gel product candidate named Savvy® (C31G).

DIVERSIFIED PRODUCT PIPELINE

CORPORATE NEWS EXPECTED TO ESCALATE OVER 2ND QUARTER PERIOD

Disclaimer: Heritage First Capital & Equity Research Group (HFC), based upon information supplied by sources believed
to be reliable, herein prepared all material. This opinion contains forward-looking statements that involve risks and
uncertainties. A company's actual results could differ materially from those described in any forward-looking statements
discussed herein. This material is for informational purposes only and should not be construed as an offer or solicitation
of an offer to buy or sell securities. HFC is not a licensed broker, broker dealer, market marker, investment banker,
financial advisor, analyst or underwriter. Please note that HFC has been compensated in cash directly by the Company.

Copyright © 2011 Heritage First Capital / www.heritagefirst.com / Tel. 407.444.5959 / Greater Orlando